The angiotensinogen M235T and aldosterone synthase C-344T gene polymorphisms have been associated with cardiac and structure function. However, these associations in untreated hypertension remain unknown. We examined whether these variants determined both echocardiography indices and the potential associated underlying mechanisms, including cystatin-C and vascular inflammation.
Background
The angiotensinogen M235T and aldosterone synthase C-344T gene polymorphisms have been associated with cardiac and structure function. However, these associations in untreated hypertension remain unknown. We examined whether these variants determined both echocardiography indices and the potential associated underlying mechanisms, including cystatin-C and vascular inflammation.
Methods
The study population consisted of 319 untreated patients and 191 healthy individuals. Polymorphisms were determined by polymerase chain reaction technique. Left cardiac indices of geometry and function were assessed by echocardiography. Cystatin-C, intracellular cell adhesion molecule 1, and vascular cell adhesion molecule 1 levels were measured by enzyme-linked immunosorbent assay, whereas high sensitivity C-reactive protein levels were measured by immunonephelometry.
results
There was no significant interaction between the angiotensinogen genotypes on left ventricular mass index (LVMI) and diastolic function indices in all study groups. Regarding C-344T polymorphism, TT homozygous hypertensive subjects exhibited higher values of LVMI compared with C allele carriers (P = 0.02) and higher prevalence of concentric hypertrophy (P < 0.001). However, this polymorphism was not associated with variations in left atrial volume and diastolic dysfunction. Cystatin-C levels were correlated with LVMI values (r = 0.22; P = 0.002) and mean E/A ratio (r = −0.24; P < 0.001). Interestingly, a linear increase of LVMI with cyctatin-C quartiles has been revealed (F = 5.01; P < 0.001). Moreover, post hoc tests showed that increased levels of cystatin-C (above 75th percentile) were significantly different between both the first (P = 0.009) and the second quartile (P = 0.02).
The renin angiotensin-aldosterone system (RAAS) plays a crucial role in blood pressure (BP) regulation and sodium homeostasis as well as in cardiovascular conditions. 1, 2 Several studies have investigated the effects of different genetic polymorphisms on cardiovascular disease and, more particular, of those coding for components of the RAAS. 3 Also, recent data have demonstrated that left ventricular (LV) indices and geometry offer further information concerning the cardiovascular risk of hypertensive patients. Even though LV hypertrophy (LVH) has been suggested as an adaptative mechanism in states of pressure or volume overload, it has also been strongly associated with the prediction of cardiovascular morbidity and mortality in hypertension. 4, 5 The gene encoding angiotensinogen (AGT) has been shown to be associated with BP and plasma angiotensin levels. 6, 7 Moreover, scarce data have suggested that the M235T variant may be associated with ventricular hypertrophy in hypertensive patients. 8 Furthermore, epidemiological studies have suggested that C-344T, a genetic variant of aldosterone synthase (CYP11B2) gene, may affect LV mass in essential hypertension even though the results are conflicting in different populations. 9, 10 With regard to underlying mechanisms and potential contributing factors, emerging data have suggested that subclinical inflammation and cystatin-C could be associated with these alterations. 11, 12 Of note, there is evidence that cystatin-C may be associated with LV mass in hypertensive patients and could be a marker for cardiac hypertrophy in these patients. 12 To date, scarce data exist examining the combined influence of M235T and C-344T variants in LVH and cardiac indices, such as diastolic dysfunction in untreated hypertension. Therefore, in this study, we examined whether these variants determined both echocardiography indices and the potential associated underlying mechanisms.
Methods study population
We enrolled 319 untreated patients with newly diagnosed stage I-II essential hypertension who were referred to our outpatient hypertension unit within a period of 24 months. A control group, which consisted of 191 age-matched, body mass index-matched, and sex-matched normotensive, healthy individuals, was also included. All patients underwent complete physical examination and routine blood and urine biochemical analyses, with the intention of assessing the presence and extent of target organ damage. The presence and severity of hypertension were determined on the basis of office BP measurements according to the 2007 Guidelines of the European Society of Hypertension and the European Society of Cardiology. 13 Diagnosis of hypertension was based on 3 outpatient measures using automatic sphygmomanometers (Microlife BP A100 plus, Microlife AG, Switzerland) and confirmed by daytime ambulatory BP. Ambulatory BP was recorded over a working day using the automatic Spacelabs units 90207 (Redmond, WA). Blood pressure measurements were taken between 7:00 am and midnight (awake period), and between midnight and 7:00 am were (asleep period), with the device programmed to record a subject's BP every 20 minutes during the awake period and every 30 minutes during the asleep period.
Basic demographic data, current BP status, and information on associated diseases, current medication, sodium intake, and current pharmacological treatment were obtained for all subjects. They also underwent anthropometric and BP measurements, a standard 12-lead electrocardiogram, and laboratory determinations. Patients with suspicion of secondary hypertension; inflammatory, neoplastic, hepatic, and/or renal disease; chronic heart failure (New York Heart Association class III and IV); and diabetes mellitus were excluded. The study was approved by the institutional ethics committees, and informed consent was given by all participants.
Biomarkers measurements
Blood samples were obtained after an 8-12-hour overnight fast. Samples were collected in sterile tubes, centrifuged at 3000 g for 10 minutes at 48 °C, and then stored at −80 °C until assayed. Plasma was recovered by centrifugation, and biochemical parameters were determined by standard validated automatic methods using commercially available reagents. Levels of fibrinogen and C-reactive protein (CRP) were measured by immunonephelometry (Dade Behring, Marburg, Germany). Circulating levels of intercellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1) were measured by enzymelinked immunosorbent assay (ELISA). Serum cystatin-C levels were measured by BioVendor's Human Cystatin-C ELISA kit (BioVendor R&D, Candler, NC). echocardiography A 2-dimensionally guided M-mode echocardiogram was performed on each participant on the same visit by an expert sonographer. Accurate linear measurements of interventricular septal wall thickness (IVST), posterior wall thickness (PWT), and LV internal dimensions, including end diastolic/systolic diameters, were obtained. LV mass index (LVMI) was calculated by Devereux's formula 14 considering the diastolic measurements of LV internal diameter (LVID), IVST, and PWT: LVMI (g/m 2 ) = (1.04 [(IVST + LVID + PWT)3 -LVID3] -14 g)/body surface area. The geometric classification is based on the combination of increased relative wall thickness and LVH (LVMI > 115 g/m 2 for men, > 95 g/m 2 for women) at end diastole. 14 More specifically, the pattern of concentric hypertrophy is associated with high systolic BP and high peripheral resistance, whereas eccentric LVH is associated with normal peripheral resistance but high cardiac index. Also, concentric remodeling (normal LV mass with increased relative wall thickness) is characterized by high peripheral resistance and low cardiac index. 15 Left atrial volume (LAV) was calculated by the ellipsoid model according to the formula:
, where D1 is the long axis (ellipsoid) and D2 and D3 are orthogonal shortaxis dimensions and indexed by body surface area (LAVI). Normal values of LAVI have been determined in a number of studies to be 22 ± 6 ml/m 2 . 15 Ejection fraction was estimated with 2-dimensional echocardiography, as is done routinely in our laboratory, as well as mitral pulse-wave Doppler E/A ratio (Em/Am), deceleration time, and isovolumic relaxation time. Measurements of myocardial diastolic velocities at five sites on the mitral annulus including peak early myocardial tissue velocity (E), peak late myocardial tissue velocity (A) and the mean ratio E/A were obtained. The sample volume of the pulsed wave Doppler was located at the mitral annulus, and recording was performed from the septal, lateral, anterior, inferior, and posterior portions of the annulus.
dna extraction and genotyping
Approximately 5 ml of blood was collected in tubes containing ethylenediaminetetraacetic acid, and DNA was extracted using standard methods (QIAamp DNA blood kit; Qiagen, West Sussex, UK). For the detection of the AGT M235T polymorphism (rs699), we used polymerase chain reaction (PCR)-restriction fragment length polymorphism analysis. The following flanking intronic primers were used to amplify a part of the gene (by PCR): rs699F: 5′GATGCGCACAAGGTCCTG-3′; and rs699R: 5′CAGGGTGCTGTCCACACTGGCTCG-3′. The resulting product (303 base pairs) was digested by SfaNI restriction endonuclease (3 hours at 37 °C and resolution by electrophoresis at 2% agarose gel).
Subjects were genotyped for the −344 promoter polymorphism using primers CAGGAGGAGACCCCATGTGAC (sense) and CCTCCACCCTGTTCAGCCC (antisense), and the cycling conditions are reported in Table 1 . Regarding the analysis of the CYP11B2-344C/T polymorphism, PCR products were digested with HaeIII for 2 hours at 37 °C. The 344T allele lacks the HaeIII site (GGCC) present in the 344C allele. In the presence of the −344C allele, the PCR product (152 base pairs) was cut into 2 fragments of 97 base pairs and 56 base pairs. Reactions were subjected to electrophoresis in 2% agarose gels, and fragments were visualized after ethidium bromide staining under ultraviolet light. For PCR quality control, 5% of the samples were randomly selected and genotyped twice, which yielded 100% concordance.
statistical analysis
A χ 2 was used to examine whether the allele frequencies conformed to Hardy-Weinberg equilibrium proportions. Qualitative variables are presented as absolute frequencies. Continuous variables were tested for normal distribution by Kolmogorov-Smirnov test and are presented as mean plus/minus SD, whereas not normally distributed data were log transformed for analysis and are presented in the nonlogarithmic format as medians with 25-75 percentiles. Differences in continuous variables between 2 groups were assessed by the independent Student t test. Differences between categorical data were assessed by χ 2 analysis. For normally distributed data, 1-way analysis of variance was performed to examine for intergroup differences. Differences in values between study subgroups were tested by using post hoc analysis after Scheffe correction for multiple comparisons. Regression analysis was used to test for independent associations between dependent variables and known confounders, and they were expressed as β coefficient or odds ratio (OR) with 95% confidence intervals (CIs). All tests were 2-sided, and β < 0.05 was considered to indicate statistical significance. SPSS version 18.0 (SPSS, Chicago, IL) software was used for all the statistical calculations.
results
The demographic characteristics of the participants are shown in Table 2 .
effects of M235T polymorphism on echocardiographic measurements
We observed a significant difference in PWT values between TT homozygosity and M-allele carriers in the group of hypertensive subjects (ΜΜ + MT vs. TT: 8.6 ± 1.6 vs. 9.0 ± 1.4 mm; P = 0.04) but not in IVST values (10.1 ± 1.4 vs. 10.4 ± 1.4 mm; P = 0.12). In addition, no significant interaction between the AGT genotypes was observed on LVMI, both in control subjects and in hypertensive subjects (ΜΜ + MT vs. TT: 75.1 ± 15.4 vs. 71.5 ± 13.6 g/m 2 , P = 0.50; 85.1 ± 19.3 vs. 88.5 ± 21.8 g/m 2 , P = 0.27, respectively) (Figure 1 ). Moreover, no difference was detected in the prevalence of LVH (P = 0.10). Table 3 summarizes the M-mode, Doppler, and tissue Doppler echocardiographic measurements for the study genotypes among groups.
the effect of the C-344T polymorphism on echocardiographic measurements
Regarding to the C-344T polymorphism, significant main effects of the promoter genotype on LVMI have been revealed (Table 3 ). The data on LV diameters, mass, and diastolic function indices, however, were not consistent with a gene dosage effect, such that these measurements did not increase in a linear relationship with the number of 344T alleles carried by each subject. More specifically, we have observed higher values of LVMI in −344TT homozygosity compared with M-allele carriers in the group of hypertensive subjects (88.2 ± 30.2 vs. 79.9 ± 24.6 g/m 2 ; P = 0.02) (Figure 2 ). Accordingly, we tested the association between TT homozygosity and LVMI after adjustments for confounders including sex, age, smoking status, systolic and diastolic arterial pressure, and creatinine and CRP levels.
Of note, regression analysis revealed that TT homozygosity was, independently of the aforementioned confounders, associated with LVMI (β coefficient = 9.29, 95% CI = 0.56-18.01; P = 0.04) (Table 4) . Moreover, logistic regression revealed that TT homozygosity, after adjustment for the aforementioned confounders, was independently associated with concentric hypertrophy (OR = 10.37, 95% CI = 2.11-50.81; P = 0.004) (Table 3) . However, TT homozygosity of the CYP11B2 promoter genotype predicted nonsignificant variations in left atrial volume (P = 0.12), and this difference remained marginally nonsignificant in TT homozygous compared with C-allele carriers in LAVI values (23.1 ± 5.0 vs. 21.6 ± 4.6 ml/m 2 ; P = 0.05). Similar results were obtained regarding the mean E/A ratio, which differed between the groups of TT homozygous subjects and C-allele carriers in hypertension, although not significantly (0.90 ± 0.29 vs. 0.85 ± 0.37; P = 0.06).
cystatin-c and inflammatory biomarkers
We have found that cystatin-C levels correlated with LVMI values (r = 0.22; P = 0.002) and mean E/A ratio (r = −0.24; P < 0.001) in the group of hypertensive subjects. With respect to renal function, C-allele carriers of C-344T polymorphism did not exhibit higher values of cystatin-C compared with TT homozygous hypertensive subjects (821.3 ± 190.8 vs. 819.0 ± 205.0 ng/ml; P = 0.94). However, in subgroup analyses, there were significant associations of cystatin-C with LVMI in the group of T allele hypertensive carriers but not in CC homozygotes (r = 0.23, P = 0.004 vs. r = −0.02, P = 0.90). We performed linear regression analysis and tested the association between cyctatin-C levels and LVMI after adjustments for confounders including sex, age, smoking status, systolic arterial pressure, diastolic arterial pressure, and CRP levels. Thus, regression analysis revealed that cyctatin-C levels are, independently of the aforementioned confounders, associated with LVMI (b = 0.032, 95% CI = 0.009-0.056; P = 0.007) ( Table 5 ). The range of cystatin-C concentrations for all patients by quartiles is as follows: quartile 1: ≤693 ng/ ml; quartile 2: 694-799 ng/ml; quartile 3: 800-919 mg/L; and quartile 4: ≥0.93 ng/ml. Interestingly, analysis of variance revealed a linear increase of LVMI with cyctatine-C quartiles (quartile 1: 82.7 ± 17.3; quartile 2: 80.3 ± 16.2; quartile 3: 86.6 ± 19.5; quartile 4: 95.8 ± 23.0 g/m 2 ; F = 5.01; P < 0.001). Moreover, post hoc tests after Scheffe correction for multiple comparisons showed that increased levels of cystatin-C (above 75th percentile) were significantly different between both the first (P = 0.009) and the second quartiles (P = 0.02) (Figure 3 ).
Patients with hypertension had higher CRP levels compared with control subjects (1.4 (95% CI = 0.60-2.91) vs. 0.95 (95% CI = 0.37-2.3) mg/L; P = 0.01). However, as we have previously shown, the M235T polymorphism on AGT gene had no significant effect on inflammatory biomarkers (P = not significant for all). 16 Similarly, no significant differences were observed in CRP, ICAM, and VCAM levels with respect to C-344T genotypes for all the study groups (P = not significant for all). Also, CRP, VCAM-1, and ICAM-1 were not associated with LVMI values (P = not significant for all).
discussion
In this study, we have investigated 2 gene polymorphisms of the RAAS for association with echocardiographic measurements. More specifically, we searched for associations of the angiotensinogen gene M235T polymorphism and of the aldosterone synthase gene C-344T with indices of LVH and diastolic function. Our study showed no significant interaction between the AGT genotypes on LV mass or diastolic function indices in both control and hypertensive subjects. We also observed that variations in the CYP11B2 gene are associated with LVMI and concentric hypertrophy. The influence of CYP11B2 gene polymorphism is independent of classic risk factors and any other cardiovascular comorbidity. Importantly, increased levels of cystatin-C, but not inflammatory biomarkers, were correlated with higher LVMI values.
Several studies have indicated the important role of the AGT gene for the predisposition to essential hypertension, suggesting that single nucleotide polymorphisms could be associated with the risk of essential hypertension. In accordance, several data have shown that the 235T allele may be linked to increased risk of hypertension. 17 We have recently Eccentric hypertrophy, % 1.6 0 1.5 1.6
Datas are mean + SD unless otherwise noted. Abbreviations: BMI, body mass index; CRE, creatinine; DAP, diastolic arterial pressure; E/A, peak early myocardial tissue velocity/peak late myocardial tissue velocity mean ratio from portions of the annulus; Em/Am, mitral pulse wave Doppler E/A ratio; IVST, interventricular septal wall thickness; LAD, long axis left atrial diameter; LAVI, left atrial volume index; LVMI, left ventricular mass index; PWT, posterior wall thickness; RWT, relative wall thickness; SAP, systolic arterial pressure.
a P values are calculated with t test or χ 2 test.
shown that that this polymorphism is associated with the risk of hypertension and increased arterial stiffness in hypertensive subjects independently of inflammatory mechanisms. 16 Nevertheless, it has also been shown that the 235T allele could be a marker for AGT production, with carriers of the 235T variant showing, on average, higher plasma levels of AGT, which might affect the degree of the RAAS activation and, in turn, influence the formation rate of angiotensin II. 18 Only a few small-scale studies exist investigating the potential impact of AGT M235T polymorphism and cardiac indices in hypertension. Previously, the results concerning the association of this polymorphism with LV mass or LVH have been contradictory, and only few data support this possibility. [19] [20] [21] Specifically, the higher incidence of LVH in T homozygosity could be explained by the activation of the circulating (or local) RAS and/or by a higher BP level. 17 Ιn a random cohort of 430 hypertensive and 426 control subjects, Kauma et al. 19 have demonstrated similar values in the adjusted LV mass between the different genotypes of M235T polymorphism among either the hypertensive or the control subjects. On the contrary, other investigators have shown that the TT genotype of the AGT gene could be considered a risk factor for the development of cardiac hypertrophy in the hypertensive population. 21 Furthermore, it remains unknown whether a significant quantity of diastolic dysfunction's variation, as well as the type of hypertrophy, are under the AGT gene.
Our data suggest that AGT genotypes are not associated with LV mass values in essential hypertension or diastolic function indices, such as mitral pulse-wave Doppler Em/ Am and mean E/A ratio obtained by tissue Doppler imaging. Moreover, we observed that the prevalence of LVH evaluated by echocardiogram and structure-related phenotypes is similar among different genotypes and patients in the top quartile of LVMI did not show a greater prevalence of T allele compared with the rest of the study population.
A growing body of literature has suggested that C-344T polymorphism affects LV mass and thickness independently of adrenal aldosterone. 22 Sookoian et al. 23 conducted a systematic review of the literature by means of a meta-analysis to evaluate the influence of C-344T polymorphism on LV mass and related phenotypes. From a total of 2,157 subjects, it was shown that homozygous TT hypertensive subjects had 6.9% increased LVM and that PWT was lower in homozygous CC individuals. However, they observed no significant association between LVM and the C-344T variant. 23 Yet, the potential impact of this variant on LVMI and diastolic dysfunction has not been elucidated nor have their associations with indices of LA volume and specific types of LV geometry been explored. There are data contradicting to a strong influence of the aldosterone synthase C-344T polymorphism on LV size and discrepant data on the association with serum aldosterone levels. 24, 25 Our study demonstrates that TT homozygous hypertensive subjects exhibited significantly higher values of LVMI and higher prevalence of concentric hypertrophy compared with C-allele carriers and, similarly, TT homozygosity has predicted variations in LAVI, even though this difference did not reach statistical significance. With regards to the latter, however, this association must be taken with caution because of the small sample size of data available for LAVI values. Additionally, similar results were obtained regarding diastolic function as indicated by the mean E/A ratio. We have observed a trend toward lower mean E/A ratio in the group of TT homozygous subjects compared with C-allele carriers in hypertension, although this difference did not reach statistical significance.
In this study, we found that cystatin-C is associated with LVMI and diastolic function in untreated hypertension. Notably, a linear increase of LVMI with cyctatine-C quartiles was also revealed.
Three hypotheses that potentially explain the association of cystatin-C with LVH have been suggested. Cystatin-C, as a better estimate of renal function, could be a stronger predictor of preclinical changes in cardiovascular structure. In addition, cystatin-C potentially is associated primarily with hypertension, and it could even directly participate in the development of LVH geometry. With respect to the latter, the balance between cysteine proteases (cathepsin B, S, K) and cysteine protease inhibitors (cystatin-C) has been implicated in the pathogenesis of cardiac remodeling in hypertrophied and failing hearts. 26, 27 Although the pathophysiological link between cystatin-C and LVH is unknown, the interrelationships of these 2 protein families may lead to the development of hypertrophy.
In our study, we have shown that inflammatory biomarkers were not affected genetically, while they were not associated with LV mass. In controversy with our results, the PIVUS study 11 indicated that inflammatory markers such as ICAM-1, VCAM-1, and high-sensitivity CRP were associated with LVH and diastolic dysfunction. Further to indirect cardiovascular effects, aldosterone has been suggested to play a role on the heart through increased oxidative stress and inflammation. 28, 29 Moreover, according to Edelmann et al., 30 higher aldosterone levels were independently related to concentric LVH, thus CYP11B2 genotype effects on aldosterone levels could be a reasonable mechanism for our observations.
In this study, we have shown that C-344T aldosterone synthase, but not angiotensinogen gene variant, potentially predicts higher values of LVMI and concentric hypertrophy in untreated hypertension independently of renal function and subclinical inflammation. Moreover, we found that the increased levels of cystatin-C, but not inflammatory biomarkers, were correlated with higher LVMI values. 
